Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In view of the global emergency posed by lack of access to highly active antiretroviral therapy (HAART) and the limitations of current drug regimens, alternative therapeutic strategies are urgently needed. Cellular immune responses elicited by HIV-1 exert some control over virus replication, therefore the enhancement of HIV-1-specific responses by therapeutic vaccination might lead to viral containment without HAART. We evaluated the safety and immunogenicity, in HIV-1-infected individuals under HAART suppression, of a DNA vaccine, pTHr.HIVA.


Journal article



Publication Date





1321 - 1323


AIDS Vaccines, Adult, Antiretroviral Therapy, Highly Active, Cohort Studies, Drug Evaluation, Enzyme-Linked Immunosorbent Assay, Epitopes, Female, Genes, gag, HIV Infections, HIV-1, Humans, Immunity, Cellular, Immunization, Leukocytes, Mononuclear, Male, Vaccines, DNA